BRIEF — Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2 — Breast Cancer

Oct 13 (Reuters) — Prelude Therapeutics Incorporated: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate Kat6a Selective Degrader Prt13722 In Combination With Verzenio® And Inluriyo® In Patients With Hr+/her2- Breast Cancer Prelude Therapeutics Incorporated - Agreement Supports Evaluation Of Prt13722 With Abemaciclib And Imlunestrant In Phase 1 Trial Prelude Therapeutics Incorporated - Expects To Begin Enrollment For Phase 1 Trial In Q4 2026 Prelude Therapeutics Incorporated - Maintains Full Global Development And Commercial Rights To Prt13722 Source text:... Further company coverage: PRLD.O (Reuters.Briefs@thomsonreuters.com;)